Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 1/20 | 0.36 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.32 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | METAP2 | P50579 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5072427 | 0.81 | CYP1A2 (0.48) | METAP1METAP2 | |
| SCHEMBL8229893 | 0.81 | CYP1A2 (0.48) | METAP1METAP2 | |
| SCHEMBL20830414 | 0.80 | OPRM1 (0.44) | PLA2G1BPLA2G2AOPRM1METAP2 | |
| SCHEMBL1825503 | 0.78 | ALDH1A1 (0.41) | OPRM1 | |
| SCHEMBL24684546 | 0.76 | ALDH1A1 (0.47) | PLA2G1BPLA2G2AOPRM1METAP2 | |
| SCHEMBL9205702 | 0.76 | ALDH1A1 (0.47) | PLA2G1BPLA2G2AOPRM1METAP2 | |
| SCHEMBL9209780 | 0.76 | ALDH1A1 (0.47) | PLA2G1BPLA2G2AOPRM1METAP2 | |
| SCHEMBL9210264 | 0.76 | ALDH1A1 (0.47) | PLA2G1BPLA2G2AOPRM1METAP2 | |
| SCHEMBL9213467 | 0.74 | ALDH1A1 (0.49) | PLA2G1BPLA2G2AMETAP2 | |
| SCHEMBL9212147 | 0.74 | ALDH1A1 (0.49) | PLA2G1BPLA2G2AMETAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1957073-A2 | MEDICINAL DRUG | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007066784-A2 | DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-06-14 | — | — | WO | disclosed |